Cetuximab Combined With — FOLFIRI, FOLFOX or Radiation

Cetuximab is given through a drip — an intravenous infusion — usually before the chemotherapy begins on the same day. The first infusion is given slowly because your team will watch for any immediate reaction; subsequent infusions are typically shorter. CION administers cetuximab-based regimens as day care, so most patients do not need to stay overnight.

Cetuximab works by blocking the EGFR receptor, but if your tumour has a RAS mutation further along the same growth pathway, the signal continues even when EGFR is blocked. In that situation, cetuximab adds side effects without adding benefit. NCCN and ESMO guidelines treat a RAS mutation in colorectal cancer as a reason not to use cetuximab at all. Testing is done on tissue from your existing biopsy and does not usually require a new procedure.

The most common effect cetuximab adds is a skin rash, typically on the face, scalp and upper body. It is managed with creams and sometimes oral antibiotics, and does not usually require cetuximab to be stopped. Low magnesium is another effect — your team will monitor this through blood tests. Infusion reactions such as flushing or breathlessness can occur, particularly with the first dose, which is why it is given with monitoring.

There is no universal answer. The choice depends on your treatment history, what side effects are most important to avoid, and whether this is a first or later line of treatment. FOLFOX carries a risk of peripheral neuropathy — numbness and tingling in the hands and feet — that accumulates with each oxaliplatin cycle. FOLFIRI uses irinotecan instead, which more commonly causes loose motions and sometimes hair thinning. Your oncologist chooses the regimen that fits your situation, not because one is always more effective than the other.

Cetuximab combined with radiation is not a standard approach in colorectal cancer. That combination is established specifically for locally advanced head and neck squamous cell carcinoma. In colorectal cancer, cetuximab is paired with FOLFIRI or FOLFOX, not with radiation. Radiation may be used separately in colorectal cancer — particularly for rectal cancer — but in a different context and without cetuximab. If radiation has been mentioned in your plan, ask your oncologist which part of your treatment it belongs to.

Response is assessed through imaging — usually a CT scan — after a set number of treatment cycles. Your oncologist measures whether tumours have shrunk, stayed stable, or grown. Blood tumour markers such as CEA may also be tracked alongside scans, though scans remain the primary tool. A skin rash from cetuximab has been associated with treatment activity in published studies, but it is not a reliable measure of response on its own — your oncologist will not use it to make decisions about your plan.